✦ LIBER ✦

Time/dose-response treatment of chronic NANB hepatitis with recombinant interferon alfa. A multi-center controlled trial. (Preliminary report)

Book ID: 122633037
Publisher: Elsevier Science
Year: 1991
Tongue: English
Weight: 73 KB
Volume: 13
Category: Article
ISSN: 0168-8278
DOI: 10.1016/0168-8278(91)91570-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of chronic NANB viral hepatiti

Treatment of chronic NANB viral hepatitis with recombinant interferon alfa-2b. Preliminary clinical and immunologic results

✍ Garda-Buey, L; Garcia-Monzon, C; Garcia-Sanchez, A; Pajares, JM; Moreno-Otero, R 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 76 KB

Long-term treatment with low doses of in

Long-term treatment with low doses of interferon ALFA-2B (rIFNa2b) in patients with chronic non-A, non-B (NANB) hepatitis: Data of a multicenter randomized prospectively controlled trial

✍ Müller, R.; Baumgarten, R.; Markus, R.; Beckh, K.H.; Loeschke, K.; Stremmel, W.; 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 107 KB

Lymphoblastoid interferon alfa-n1 improv

Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial

✍ Geoffrey C. Farrell; Bruce R. Bacon; Robert D. Goldin 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

The aim of this study was to compare the short-term and long-term efficacy and safety of lymphoblastoid interferon with a recombinant interferon alfa (IFN-␣) in a 24-week treatment course for chronic hepatitis C. One thousand seventy-one patients with chronic hepatitis C were randomized to receive l

A phase II randomized, double-blind, pla

A phase II randomized, double-blind, placebo-controlled multicenter study of recombinant human interleukin-12 for the treatment of chronic hepatitis C virus infection in patients non-responsive to previous treatment with interferon-alpha with or without ribavirin: Paul J Pockros, John G McHutchison, Scripps Clinic, La Jolla, CA; Chris O'Brien, University of Miami, Miami, FL; Myron Tong, Huntingon Medical Research Institute, Pasadena, CA; Coleman Smith, Minnesota Clinical Research Center, St. Paul, MN; Vinod Rustgi, Metropolitan Research Group, Fairfax, VA; Robert L Carithers, University of Washington Medical Center, Seattle, WA; Elizabeth Olek, Genetics Institute, Cambridge, MA

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB